Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

Regorafenib is an orally administered inhibitor of protein kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment. Phase III studies showed that regorafenib has efficacy in patients with advanced gastrointestinal stromal tumors or treatment‐refractory meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Zopf, Dieter, Fichtner, Iduna, Bhargava, Ajay, Steinke, Wolfram, Thierauch, Karl‐Heinz, Diefenbach, Konstanze, Wilhelm, Scott, Hafner, Frank‐Thorsten, Gerisch, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119973/
https://www.ncbi.nlm.nih.gov/pubmed/27734608
http://dx.doi.org/10.1002/cam4.883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119973/
https://www.ncbi.nlm.nih.gov/pubmed/27734608
http://dx.doi.org/10.1002/cam4.883

Ejemplares similares